JP7465368B2 - 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 - Google Patents

血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 Download PDF

Info

Publication number
JP7465368B2
JP7465368B2 JP2022562298A JP2022562298A JP7465368B2 JP 7465368 B2 JP7465368 B2 JP 7465368B2 JP 2022562298 A JP2022562298 A JP 2022562298A JP 2022562298 A JP2022562298 A JP 2022562298A JP 7465368 B2 JP7465368 B2 JP 7465368B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
methyl
group
thia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521200A (ja
Inventor
マティアス エクハルト
マリナ クリスティナ ヴィルヴァハー
ユルゲン プレストル
フェレンツ コンテス
レオ トーマス
クリストファー ジークフリート タウターマン
ディーター ヴィーデンマイアー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023521200A publication Critical patent/JP2023521200A/ja
Priority to JP2024055696A priority Critical patent/JP7810743B2/ja
Application granted granted Critical
Publication of JP7465368B2 publication Critical patent/JP7465368B2/ja
Priority to JP2026008915A priority patent/JP2026090284A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
JP2022562298A 2020-11-16 2021-11-12 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 Active JP7465368B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024055696A JP7810743B2 (ja) 2020-11-16 2024-03-29 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
JP2026008915A JP2026090284A (ja) 2020-11-16 2026-01-22 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207719.4 2020-11-16
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024055696A Division JP7810743B2 (ja) 2020-11-16 2024-03-29 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体

Publications (2)

Publication Number Publication Date
JP2023521200A JP2023521200A (ja) 2023-05-23
JP7465368B2 true JP7465368B2 (ja) 2024-04-10

Family

ID=73543025

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022562298A Active JP7465368B2 (ja) 2020-11-16 2021-11-12 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
JP2024055696A Active JP7810743B2 (ja) 2020-11-16 2024-03-29 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
JP2026008915A Pending JP2026090284A (ja) 2020-11-16 2026-01-22 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024055696A Active JP7810743B2 (ja) 2020-11-16 2024-03-29 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
JP2026008915A Pending JP2026090284A (ja) 2020-11-16 2026-01-22 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体

Country Status (20)

Country Link
US (2) US11766443B2 (enExample)
EP (1) EP4244229A1 (enExample)
JP (3) JP7465368B2 (enExample)
KR (1) KR20230109692A (enExample)
CN (2) CN116745300A (enExample)
AR (1) AR124070A1 (enExample)
AU (1) AU2021379248A1 (enExample)
CA (1) CA3200710A1 (enExample)
CL (2) CL2023001361A1 (enExample)
CO (1) CO2023005894A2 (enExample)
CR (2) CR20230211A (enExample)
DO (1) DOP2023000090A (enExample)
EC (1) ECSP23036210A (enExample)
IL (1) IL302769A (enExample)
JO (1) JOP20230107A1 (enExample)
MX (1) MX2023005678A (enExample)
PE (1) PE20231855A1 (enExample)
SA (1) SA523440809B1 (enExample)
TW (1) TWI913356B (enExample)
WO (1) WO2022101377A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
DD265405A5 (de) * 1986-01-21 1989-03-01 Boehringer Ingelheim Kg,De Neue thieno-1,4-diazepine
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
JP2959598B2 (ja) 1990-10-12 1999-10-06 吉富製薬株式会社 光学活性なチエノトリアゾロジアゼピン化合物
CN1033327C (zh) 1991-04-23 1996-11-20 东丽株式会社 三环三唑并衍生物的制造方法
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CID 147780900，DATABASE pubchem [online]，2020年08月20日

Also Published As

Publication number Publication date
US20220160725A1 (en) 2022-05-26
CL2024000317A1 (es) 2024-07-12
AU2021379248A1 (en) 2023-06-22
TW202237620A (zh) 2022-10-01
CN117624188B (zh) 2026-08-07
CN117624188A (zh) 2024-03-01
PE20231855A1 (es) 2023-11-21
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
EP4244229A1 (en) 2023-09-20
CN116745300A (zh) 2023-09-12
JP2026090284A (ja) 2026-06-02
AU2021379248A9 (en) 2024-10-10
US11766443B2 (en) 2023-09-26
JP2023521200A (ja) 2023-05-23
ECSP23036210A (es) 2023-06-30
IL302769A (en) 2023-07-01
CR20230211A (es) 2023-07-13
SA523440809B1 (ar) 2024-10-08
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
JOP20230107A1 (ar) 2023-05-16
KR20230109692A (ko) 2023-07-20
TWI913356B (zh) 2026-02-01
CL2023001361A1 (es) 2023-11-03
MX2023005678A (es) 2023-05-26
CR20260053A (es) 2026-03-24
JP2024099528A (ja) 2024-07-25
AR124070A1 (es) 2023-02-08

Similar Documents

Publication Publication Date Title
CN105829307B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN113039181B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
JP7703587B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
WO2014101295A2 (zh) 一种詹纳斯激酶（JAKs）抑制活性的异恶唑衍生物
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2022112345A1 (en) Aryl derivatives for treating trpm3 mediated disorders
TW201902887A (zh) 做為血漿激肽釋放酶抑制劑之雜芳基甲醯胺衍生物
JP7810743B2 (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
TW202019923A (zh) 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物
JP7378470B2 (ja) 血漿カリクレイン阻害剤としてのフェニルテトラゾール誘導体
EA048242B1 (ru) Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов
JP2025501761A (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
CN121085992A (zh) 信号转导及转录激活蛋白6选择性降解剂化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240329

R150 Certificate of patent or registration of utility model

Ref document number: 7465368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150